DBV Technologies | Mutual Funds
Mutual Funds that own DBV Technologies
Oppenheimer International Small Company Fund
754,989
2.52%
0
0.32%
02/28/2018
Government Pension Fund - Global (The)
527,396
1.76%
-35,763
0%
12/31/2017
Amundi Actions France
387,783
1.29%
75,415
0.97%
01/31/2018
Vanguard Total International Stock Index Fund
335,882
1.12%
0
0%
07/31/2018
Biotech Growth Trust Plc (The)
261,044
0.87%
2,243
1.67%
09/30/2017
Invesco Funds Series 4 - Continental European Small Cap Equity
240,195
0.8%
105,448
1.34%
03/29/2018
Amundi Actions PME
176,667
0.59%
0
0.73%
01/31/2018
Exane Funds 1 - Mercury Fund
150,000
0.5%
-50,000
0.48%
02/28/2018
Amundi Funds - Equity Euroland Small Cap
142,490
0.48%
0
0.81%
01/31/2018
Vanguard Developed Markets Index Fund
133,607
0.45%
0
0.01%
07/31/2018
| Address |
177-181, avenue Pierre Brossolette
Montrouge Ile-de-France 92120
France
|
|
Employees
|
- |
| Website |
http://www.dbv-technologies.com |
| Updated |
07/08/2019 |
| DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed two products candidates: Viaskin Peanut and Viaskin Milk. |
